New RayStation 8A Release Adds Support for TomoDirect Treatment Delivery
New RayStation 8A Release Adds Support for TomoDirect Treatment Delivery |
| [20-June-2018] |
STOCKHOLM, June 20, 2018 /PRNewswire/ -- RaySearch has announced the release of RayStation® 8A*, the latest version of its innovative radiation therapy treatment planning system. The new release brings a broad range of advances, including full planning capabilities for the TomoTherapy®* and Radixact systems from Accuray, and supports the TomoDirectTM delivery mode in addition to TomoHelicalTM. Other advances in RayStation 8A include support for TomoTherapy in Plan Explorer, improvements for proton and carbon ion therapy and further integration with RayCare*®, the next-generation oncology information system. The release of RayStation 8A is one more step towards RaySearch's goal of unifying treatment planning for as many treatment delivery systems as possible, eliminating the complications and additional steps that arise from using multiple software systems. All TomoTherapy and Radixact users now have access to advanced RayStation features, including multi-criteria optimization (MCO), adaptive planning and Plan Explorer. With the addition of Plan Explorer functionality, TomoTherapy and Radixact clinics can now automatically generate a large number of treatment plans for defined clinical goals and combinations of treatment techniques and machines, optimizing the use of treatment machines and increasing treatment planning efficiency. Improvements for proton and carbon ion therapy include automatic selection of range shifter for PBS machines and DICOM export of magnets in the lateral spreading device sequence for all ion treatment machines. Ion beam commissioning tools have also been refined for easier use, and carbon ion treatment machines are now supported in RayStation's physics module. RayStation 8A strengthens integration with RayCare. Other general improvements include the possibility to choose independent isocenters and/or independent directions for robust optimization, the ability to view DVHs in absolute volume and an improved user interface for DICOM import. Johan Löf, CEO of RaySearch, says: "This latest RayStation release is an important step forward. We are very pleased to expand our support for the TomoTherapy platform, giving all users access to innovative RayStation features. We have also included some significant additional features for particle therapy, which is an important focus area for RaySearch. Many more exciting developments are in the pipeline for upcoming releases, and we will announce these in the near future." About RayCare RayCare represents the future of OIS technology, developed from the ground up by RaySearch to support the complex logistical challenges of modern, large-scale radiation therapy centers. RayCare will integrate the high-performance radiation therapy algorithms available in RayStation with advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy. About RayStation RayStation integrates all RaySearch's advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch's market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability. About RaySearch RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company has now launched the next-generation oncology information system, RayCare, which comprises a new product area for RaySearch. RaySearch's software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. To learn more about RaySearch, go to: www.raysearchlabs.com * Subject to regulatory clearance in some markets. For further information, please contact: Johan Löf, President and CEO, RaySearch Laboratories AB (publ) Telephone: +46-(0)8-510-530-00 This information was brought to you by Cision http://news.cision.com The following files are available for download:
SOURCE RaySearch Laboratories | ||||
Company Codes: Bloomberg:RAYB@SS, ISIN:SE0000135485, RICS:RAYB.ST, Stockholm:RAYB |
View original content:© 2018 PR Newswire. All Rights Reserved.
#content-news .main-news{color:#737373;font-size:14px;line-height:inherit;text-align:inherit}FDA Approves Aurinia Pharmaceuticals' (Nasdaq: AUPH / TSX: AUP) LUPKYNIS (voclosporin) for Adult Patients with Active Lupus Nephritis
